Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes
Mehmet Sargin
Endocrine Journal, 2004
View PDFchevron_right
Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
Poul Strange
Diabetes Care, 2006
View PDFchevron_right
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial
Arrigo Cicero
Diabetes, Obesity and Metabolism, 2006
View PDFchevron_right
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Byron Hoogwerf
The Lancet, 2006
View PDFchevron_right
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
Philip Raskin
Diabetologia, 2000
View PDFchevron_right
Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone
J. McGill
Diabetic Medicine, 2004
View PDFchevron_right
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
Juan Barbosa
Diabetes-metabolism Research and Reviews, 2002
View PDFchevron_right
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes
Luc Van Gaal
Diabetes, Obesity and Metabolism, 2003
View PDFchevron_right
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Nigel Jones
The Lancet, 2009
View PDFchevron_right
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes
Lucio Vilar
Arquivos Brasileiros de Endocrinologia & Metabologia, 2010
View PDFchevron_right
Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome
Arrigo Cicero
Pharmacotherapy, 2005
View PDFchevron_right
A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes
Philip Raskin
Diabetes Care, 2001
View PDFchevron_right
Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy
Julius Vaz
Clinical Therapeutics, 2003
View PDFchevron_right
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
Barbara Kravitz
Diabetes, Obesity and Metabolism, 2006
View PDFchevron_right
Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes
Dimitrios Karamitsos
In vivo (Athens, Greece)
View PDFchevron_right
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis
Arvind Agrawal
Clinical Therapeutics, 2003
View PDFchevron_right
Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes
Alptekin Gursoy
Acta Diabetologica, 2007
View PDFchevron_right
Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial
mustafa noor
American Journal of Medicine, 2004
View PDFchevron_right
The Effect of Rosiglitazone on Liver in Type 2 Diabetes Patients
Jitendra Ahuja
International journal of current research and review, 2013
View PDFchevron_right
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance
Arvind Agrawal
Diabetic Medicine, 2004
View PDFchevron_right
Rosiglitazone reduces urinary albumin excretion in type II diabetes
George Bakris
Journal of Human Hypertension, 2003
View PDFchevron_right
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
mark jonh
… England Journal of …, 2006
View PDFchevron_right
Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin
Arrigo Francesco Giuseppe Cicero
Archives of Medical Research, 2008
View PDFchevron_right